Kura Oncology announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $100M of shares of its common stock. BofA Securities, Jefferies and SVB Securities are acting as joint bookrunning managers in the offering. Cantor and BTIG are acting as lead managers in the offering. JMP Securities, a Citizens Company, and H.C. Wainwright & Co. are acting as co-managers in the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KURA:
- Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
- Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants
- Kura Oncology price target raised to $25 from $24 at Stifel
- Kura Oncology to host investor day
- Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress